Medications for Hypereosinophilic Syndrome

8 results

  • Imatinib mesylate (imatinib mesylate)

    (IMATINIB MESYLATE)
    Camber Pharmaceuticals, Inc.
    Usage: This drug is indicated for treating newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome/chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).

  • Imatinib mesylate (imatinib mesylate)

    (Imatinib Mesylate)
    BluePoint Laboratories
    Usage: This drug is indicated for newly diagnosed or treatment-resistant Philadelphia chromosome positive chronic myeloid leukemia, acute lymphoblastic leukemia in adults and pediatrics, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors in adults.

  • Imatinib mesylate (imatinib mesylate)

    (imatinib mesylate)
    Archis Pharma LLC
    Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in various stages post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors.

  • Imatinib mesylate (imatinib mesylate)

    (imatinib mesylate)
    Qilu Pharmaceutical Co., Ltd.
    Usage: This drug is indicated for treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and various myelodysplastic/myeloproliferative diseases, among other conditions, including aggressive systemic mastocytosis and gastrointestinal stromal tumors.

  • Imatinib mesylate (imatinib mesylate)

    (imatinib mesylate)
    Wockhardt USA LLC.
    Usage: This drug is indicated for newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in blast crisis or after interferon failure, adult relapsed/refractory Philadelphia positive acute lymphoblastic leukemia, myelodysplastic/myeloproliferative diseases with PDGFR rearrangements, aggressive systemic mastocytosis without D816V c-Kit mutation, hypereosinophilic syndrome, and unresectable dermatofibrosarcoma protuberans.

  • Imatinib mesylate (imatinib mesylate)

    (Imatinib Mesylate)
    American Health Packaging
    Usage: This drug is indicated for newly diagnosed Philadelphia positive chronic myeloid leukemia (CML) in chronic phase, Ph+ CML in various phases post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) in adults, and newly diagnosed Ph+ ALL in pediatric patients, among other specific malignancies.

  • Imatinib mesylate (imatinib)

    (imatinib)
    Mylan Pharmaceuticals Inc.
    Usage: This drug is indicated for the treatment of various conditions including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).

  • Nucala

    (mepolizumab)
    GlaxoSmithKline LLC
    Usage: NUCALA is indicated for the add-on maintenance treatment of severe asthma in patients aged 6 years and older with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyps in adults, eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.